These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 10569939

  • 21. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
    Sukhanova A, Grokhovsky S, Zhuze A, Devy J, Pluot M, Oleinikov V, Nabiev I.
    Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
    [Abstract] [Full Text] [Related]

  • 22. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK.
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
    Laco GS, Collins JR, Luke BT, Kroth H, Sayer JM, Jerina DM, Pommier Y.
    Biochemistry; 2002 Feb 05; 41(5):1428-35. PubMed ID: 11814334
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Synthesis and evaluation of 9-benzylideneamino derivatives of homocamptothecin as potent inhibitors of DNA topoisomerase I.
    Guo W, Miao Z, Sheng C, Yao J, Feng H, Zhang W, Zhu L, Liu W, Cheng P, Zhang J, Che X, Wang W, Luo C, Xu Y.
    Eur J Med Chem; 2010 Jun 05; 45(6):2223-8. PubMed ID: 20202723
    [Abstract] [Full Text] [Related]

  • 30. Camptothecin analogues with enhanced antitumor activity at acidic pH.
    Adams DJ, Dewhirst MW, Flowers JL, Gamcsik MP, Colvin OM, Manikumar G, Wani MC, Wall ME.
    Cancer Chemother Pharmacol; 2000 Jun 05; 46(4):263-71. PubMed ID: 11052623
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues.
    Kim DK, Ryu DH, Lee JY, Lee N, Kim YW, Kim JS, Chang K, Im GJ, Kim TK, Choi WS.
    J Med Chem; 2001 May 10; 44(10):1594-602. PubMed ID: 11334569
    [Abstract] [Full Text] [Related]

  • 32. Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells.
    Lansiaux A, Facompré M, Wattez N, Hildebrand MP, Bal C, Demarquay D, Lavergne O, Bigg DC, Bailly C.
    Mol Pharmacol; 2001 Sep 10; 60(3):450-61. PubMed ID: 11502875
    [Abstract] [Full Text] [Related]

  • 33. Trifluoromethyl-promoted homocamptothecins: synthesis and biological activity.
    Zhu L, Miao Z, Sheng C, Guo W, Yao J, Liu W, Che X, Wang W, Cheng P, Zhang W.
    Eur J Med Chem; 2010 Jul 10; 45(7):2726-32. PubMed ID: 20304538
    [Abstract] [Full Text] [Related]

  • 34. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH, Andersson BS, Nelson JA.
    Cancer Biochem Biophys; 1990 Jan 10; 11(1):23-30. PubMed ID: 2159843
    [Abstract] [Full Text] [Related]

  • 35. Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues.
    Sugimori M, Ejima A, Ohsuki S, Uoto K, Mitsui I, Kawato Y, Hirota Y, Sato K, Terasawa H.
    J Med Chem; 1998 Jun 18; 41(13):2308-18. PubMed ID: 9632364
    [Abstract] [Full Text] [Related]

  • 36. Structure-activity relationship study of 16 a-thiocamptothecins: an integrated in vitro and in silico approach.
    Samorì C, Beretta GL, Varchi G, Guerrini A, Di Micco S, Basili S, Bifulco G, Riccio R, Moro S, Bombardelli E, Zunino F, Fontana G.
    ChemMedChem; 2010 Dec 03; 5(12):2006-15. PubMed ID: 21069656
    [Abstract] [Full Text] [Related]

  • 37. New homocamptothecins: synthesis, antitumor activity, and molecular modeling.
    Miao Z, Sheng C, Zhang W, Ji H, Zhang J, Shao L, You L, Zhang M, Yao J, Che X.
    Bioorg Med Chem; 2008 Feb 01; 16(3):1493-510. PubMed ID: 18207748
    [Abstract] [Full Text] [Related]

  • 38. Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
    Gamage SA, Spicer JA, Finlay GJ, Stewart AJ, Charlton P, Baguley BC, Denny WA.
    J Med Chem; 2001 Apr 26; 44(9):1407-15. PubMed ID: 11311063
    [Abstract] [Full Text] [Related]

  • 39. [Pharmacology of camptothecin and its derivatives].
    Rivory LP, Robert J.
    Bull Cancer; 1995 Apr 26; 82(4):265-85. PubMed ID: 10846537
    [Abstract] [Full Text] [Related]

  • 40. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.
    Liao Z, Robey RW, Guirouilh-Barbat J, To KK, Polgar O, Bates SE, Pommier Y.
    Mol Pharmacol; 2008 Feb 26; 73(2):490-7. PubMed ID: 17984197
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.